Auron Therapeutics, co-founded by Matt Vander Heiden, announced that the FDA has granted Fast Track designation to its therapeutic candidate, AUTX-703, paving the way for clinical development including a Phase 1 clinical trial in acute myelogenous leukemia set to open this year.